LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Search

Edwards Lifesciences Corp

Closed

SectorHealthcare

81.5 2.3

Overview

Share price change

24h

Current

Min

78.76

Max

81.7

Key metrics

By Trading Economics

Income

290M

381M

Sales

79M

1.6B

P/E

Sector Avg

41.714

51.415

EPS

0.78

Profit margin

23.092

Employees

16,000

EBITDA

382M

515M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+20.16% upside

Dividends

By Dow Jones

Next Earnings

23 Jul 2026

Market Stats

By TradingEconomics

Market Cap

-2.9B

44B

Previous open

79.2

Previous close

81.5

News Sentiment

By Acuity

44%

56%

143 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Edwards Lifesciences Corp Chart

Past performance is not a reliable indicator of future results.

Related News

10 Jan 2026, 00:16 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Drops Merger With JenaValve

6 Aug 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

Peer Comparison

Price change

Edwards Lifesciences Corp Forecast

Price Target

By TipRanks

20.16% upside

12 Months Forecast

Average 97.8 USD  20.16%

High 110 USD

Low 85 USD

Based on 17 Wall Street analysts offering 12 month price targets forEdwards Lifesciences Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

14

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

74.52 / 75.54Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

143 / 346 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat